Related Experiment Video
Updated: Mar 23, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
Giant cell aortitis: clinical presentation and outcomes in 40 patients consecutively operated on
Maude Gagné-Loranger1, Éric Dumont1, Pierre Voisine1
1Department of Cardiovascular Surgery, Quebec Heart and Lung Institute, Laval University, Sainte-Foy, Canada.
Insights
Giant cell arteritis (GCA) of the thoracic aorta, though often undiagnosed preoperatively, can be surgically managed with excellent outcomes. Regular imaging follow-up is crucial for monitoring aortic progression in these patients.
Area of Science:
- Cardiovascular Surgery
- Rheumatology
- Vascular Surgery
Background:
- Giant cell arteritis (GCA) primarily affects medium and large arteries.
- While temporal arteritis is well-defined, GCA involving the thoracic aorta is less understood.
- This study addresses the clinical characteristics and surgical outcomes of thoracic aorta GCA.
Purpose of the Study:
- To evaluate the clinical presentation of patients undergoing surgery for GCA of the thoracic aorta.
- To assess the surgical and mid-term outcomes in this patient cohort.
- To highlight the importance of postoperative imaging for disease management.
Main Methods:
- Retrospective review of patients operated for GCA of the thoracic aorta.
- Diagnosis confirmed by pathology reports.
- Analysis of clinical presentation, surgical procedures, and follow-up data.
Main Results:
- Forty patients (mean age 66.6 years) were operated on; 22.5% had a history of polymyalgia rheumatica or temporal arteritis.
- Ascending aorta involvement was universal; 85% underwent aortic arch repair. No in-hospital mortality was observed.
- The 5-year overall survival rate was 91%, with late reinterventions required in 4 patients for valve or aortic issues.
Conclusions:
- GCA of the thoracic aorta is often not suspected preoperatively (<25% of cases).
- The ascending aorta is always involved, with presentations ranging from acute to chronic.
- Surgical intervention yields excellent outcomes, necessitating mandatory follow-up imaging to track aortic progression.
Objectives:
Giant cell arteritis (GCA) may affect mid-size and large-size arteries. Although temporal arteritis is a well-characterized clinical entity, GCA of the thoracic aorta remains ill defined. The aim of the study was to evaluate the clinical presentation, surgical and mid-term outcomes in patients operated for GCA of the thoracic aorta.
Methods:
A retrospective review of patients operated for GCA of the thoracic aorta was conducted. The diagnosis of GCA was established by the pathology report.
Results:
Forty consecutive patients (mean age of 66.6 ± 9.1 years) with a diagnosis of GCA of the thoracic aorta were operated on. A history of polymyalgia rheumatica or temporal arteritis was positive in 22.5% of patients. Emergency surgery was performed in 10% of patients (3 'type A' dissections and 1 'type B'). Mega-aorta syndrome was present in 10% of patients. Involvement of the ascending aorta was present in 100% of patients. One patient had a previous branched thoracic endovascular replacement (TEVAR) with a type I proximal endoleak. In 4 patients, the thoracic aorta was totally replaced. Eighty-five percent of patients had an arch replacement; 79.4% a hemiarch and 20.6% a full arch. The mean circulatory arrest time was 16.3 ± 12.3 min. Eighty percent of patients had an aortic valve procedure; aortic valve replacement was performed in 50% of them and Bentall-De Bono/valve sparing in 50%. Cerebrovascular accident occurred in 2.5% of patients. No patient died during hospitalization. The mean hospital stay was 8.7 ± 3.0 days. The mean postoperative follow-up time was 4.2 ± 2.3 years, with a mean of 4.2 ± 2.2 thoraco-abdominal computed tomographies (CTs)/patient. Four patients had late reinterventions: 2 were valve-related, 1 for a distal type I endoleak treated with a distal TEVAR extension and 1 type II open thoraco-abdominal replacement for disease progression. One distal type I TEVAR endoleak was treated medically. Aortic diameter progressions on CT (mm/year) were 0.7 ± 1.0 mm for the arch, 1.2 ± 2.0 mm for the isthmus, 1.1 ± 1.7 mm for the mid-descending, 0.7 ± 0.9 mm for the aortic hiatus, 0.5 ± 0.5 mm for the supra-renal aorta and 0.6 ± 0.6 mm for the infra-renal aorta. One patient who declined reoperation on the descending aorta died suddenly 3 years after her initial operation. The 5-year overall survival rate was 91%.
Conclusions:
GCA of the thoracic aorta may be suspected in less than 25% of patients preoperatively. Clinical presentation may be acute or chronic with localized or diffused aortic involvement but always involved the ascending aorta. Surgery may be performed with excellent outcomes. Follow-up imaging is mandatory to assess aortic progression.
Related Concept Videos
Acute Pancreatitis II: Clinical Manifestations and Management
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Aneurysm II: Clinical Manifestations and Diagnostic Studies
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Gastritis III: Clinical Manifestations and Management
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
